'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' (vol 94, pg 115, 2018)

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共1页
• 作者

  Choueiri Toni K.; Hessel Colin; Halabi Susan; Sanford Ben; Michaelson M. Dror; Hahn Olwen; Walsh Meghara; Olencki Thomas; Picus Joel; Small Eric J.; Dakhil Shaker; Feldman Darren R.; Mangeshkar Milan; Scheffold Christian; George Daniel; Morris Michael J.;

  展开▼
• 作者单位

  Dana Farber Partners CancerCare Boston MA USA;

  Exelixis Inc San Francisco CA USA;

  Duke Univ Dept Biostat &

  Bioinformat Durham NC USA;

  Duke Univ Alliance Stat &

  Data Ctr Durham NC USA;

  Massachusetts Gen Hosp Ctr Canc Boston MA USA;

  Alliance Protocol Operat Off Chicago IL USA;

  Dana Farber Partners CancerCare Boston MA USA;

  Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;

  Washington Univ Sch Med Siteman Canc Ctr St Louis MO USA;

  UCSF Helen Diller Family Comprehens Canc Ctr San Francisco CA USA;

  Univ Kansas Wichita Wichita KS USA;

  Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

  Exelixis Inc San Francisco CA USA;

  Exelixis Inc San Francisco CA USA;

  Duke Univ Med Ctr Duke Canc Inst Durham NC USA;

  Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词